

By the end of the RheumReview program, participants will be able to: apply new approaches to assessment and diagnosis for common rheumatic diseases in clinical practice; optimize novel therapies and therapeutic strategies for patients with common rheumatic diseases in clinical practice; gain awareness of the pipeline for future developments in the management of common rheumatic diseases.

Learning Objectives

Rheumatoid Arthritis Management in Patients with Cancer

David Liew

This session will address how to navigate the management of rheumatoid arthritis in patients with cancer, including the potential impact of RA therapies on cancer recurrence and cancer therapy efficacy.

At the end of this session, participants will be able to:

1. Manage risk related to DMARDs in the context of existing cancer
2. Appreciate the reasoning behind recent guidance for RA patients with cancer
3. Understand special considerations in RA management related to immune checkpoint inhibitor therapy

CanMEDS roles

1. Medical Expert
2. Collaborator
3. Health Advocate
4. Scholar
5. Professional

Update on Dermatomyositis and Antisynthetase Syndrome

Kun Huang

This presentation explores the evolving clinical paradigm in the diagnosis and management of dermatomyositis and antisynthetase syndrome. With a focus on recent advancements in clinical assessment, we will examine the role of nailfold capillaroscopy and autoantibodies in improving diagnostic accuracy. Additionally, we will review emerging therapies and ongoing clinical trials that are shaping the future of treatment for inflammatory myositis, offering new hope for improved patient outcomes.

At the end of this session, participants will be able to:

1. Discuss the evolving clinical paradigm in dermatomyositis and antisynthetase syndrome
2. Address the latest advancements in clinical assessment and the role of autoantibodies.
3. Review the emerging therapies and clinical trials for inflammatory myositis.

CanMEDS roles

1. Medical Expert
2. Collaborator
3. Health Advocate
4. Scholar

How to Manage Soft Tissue Residual Pains in Well Controlled Inflammatory Patients in an Office Setting

Max Sun

This session will address the underlying nature of chronic soft tissue pains and the steps you can take to treat patients with this condition.

At the end of this session, participants will be able to:

1. Recognize widespread soft tissue pains in the office
2. Demonstrate a time efficient approach to dealing patients in inflammatory disease remission
3. Initiate first steps to treat these patients and identify when to consider referral to a pain clinic

CanMEDS roles

1. Communicator
2. Collaborator
3. Health Advocate

What Rheumatologists Should Know About Autoimmune Bowel Diseases

Christopher Ma

This session will give a rapid update on major advances in Crohn's disease, ulcerative colitis, and immunotherapy-induced colitis

At the end of this session, participants will be able to:

1. Discuss the assessment of patients with IBD
2. Review therapeutic advances in IBD in 2024
3. Describe updates in immune checkpoint inhibitor therapy induced colitis

CanMEDS roles

1. Medical Expert
2. Collaborator
3. Scholar

Autoinflammatory Disease: When to Consider and How to Investigate

Hugues Allard-Chamard

This session will focus on autoinflammatory disorders in adults and their presentation as well as their targeted treatments. The participant will learn on how to investigate auto inflammatory syndrome and how autoinflammation can be part of some polygenic disorders.

At the end of this session, participants will be able to:

1. Identify key features in each category of autoinflammatory disorders
2. Recognize the main treatment used for auto inflammatory disorder
3. Describe how the presence of auto inflammation affects the development and manifestation of polygenic disorders

CanMEDS roles

1. Medical Expert
2. Communicator
3. Health Advocate

Approach to Cutaneous Lupus for the Rheumatologist

Victoria Werth

This presentation will review clinical findings of cutaneous lupus erythematosus, the work-up of such patients, and approaches to treatment.

At the end of this session, participants will be able to:

1. Recognize the most common skin manifestations of cutaneous lupus
2. Identify the implications for testing for co-morbidities in patients with CLE
3. Utilize the treatment algorithms most commonly used in patients with CLE

CanMEDS roles

1. Medical Expert
2. Communicator
3. Collaborator